Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jul 7;60(1):2200581.
doi: 10.1183/13993003.00581-2022. Print 2022 Jul.

Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough

Hossein-Ardeschir Ghofrani  1   2   3
Affiliations
Free article
Editorial

Selexipag for inoperable CTEPH: why meeting a primary endpoint simply isn't enough

Hossein-Ardeschir Ghofrani. Eur Respir J. .
Free article
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: H-A. Ghofrani reports grants paid to institution from German Research Foundation (DFG), German Ministry for Research and Education (BMBF), Actelion/Janssen and Bayer; consulting fees from Actelion/Janssen, Bayer, MSD, Accelleron, MorphogenIX and Gossamer Bio; lecture honoraria from Actelion/Janssen, Bayer, MSD and Gossamer Bio; travel support from Actelion/Janssen, Bayer, Gossamer and MSD; outside the submitted work.

Comment on

  • Selexipag for the treatment of chronic thromboembolic pulmonary hypertension.
    Ogo T, Shimokawahara H, Kinoshita H, Sakao S, Abe K, Matoba S, Motoki H, Takama N, Ako J, Ikeda Y, Joho S, Maki H, Saeki T, Sugano T, Tsujino I, Yoshioka K, Shiota N, Tanaka S, Yamamoto C, Tanabe N, Tatsumi K; Study Group. Ogo T, et al. Eur Respir J. 2022 Jul 7;60(1):2101694. doi: 10.1183/13993003.01694-2021. Print 2022 Jul. Eur Respir J. 2022. PMID: 34824052 Free PMC article. Clinical Trial.

LinkOut - more resources